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Abstract: Obesity and the subsequent reprogramming of the white adipose tissue are linked 
to human disease-complexes including metabolic syndrome and concurrent non-alcoholic 
fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The dietary imposed 
dyslipidemia promotes redox imbalance by the generation of excess levels of reactive oxygen 
species and induces adipocyte dysfunction and reprogramming, leading to a low grade systemic 
inflammation and ectopic lipid deposition, e.g., in the liver, hereby promoting a vicious circle 
in which dietary factors initiate a metabolic change that further exacerbates the negative 
consequences of an adverse life-style. Large epidemiological studies and findings from 
controlled in vivo animal studies have provided evidence supporting an association between 
poor vitamin C (VitC) status and propagation of life-style associated diseases. In addition, 
overweight per se has been shown to result in reduced plasma VitC, and the distribution of 
body fat in obesity has been shown to have an inverse relationship with VitC plasma levels. 
Recently, a number of epidemiological studies have indicated a VitC intake below the 
recommended daily allowance (RDA) in NAFLD-patients, suggesting an association between 
dietary habits, disease and VitC deficiency. In the general population, VitC deficiency 
(defined as a plasma concentration below 23 μM) affects around 10% of adults, however, 
this prevalence is increased by an adverse life-style, deficiency potentially playing a broader 
role in disease progression in specific subgroups. This review discusses the currently available 
data from human surveys and experimental models in search of a putative role of VitC 
deficiency in the development of NAFLD and NASH. 
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1. Introduction 
Obesity has become an epidemic with detrimental effects on health and wellbeing. In 2013, more 
than one-third of the world’s adult population could be characterized as being overweight or obese  
(body mass index (BMI) ≥25 kg/m2) [1]. Obesity has been found to result in dysfunctional adipose tissue, 
low-grade systemic inflammation and redox imbalance with increased oxidative stress [2–4]. As part of 
the so-called metabolic syndrome, known associations with obesity include a wide range of diseases, 
e.g., atherosclerosis, insulin resistance (IR), type 2 diabetes and non-alcoholic fatty liver disease 
(NAFLD) [5]. The development of NAFLD is closely linked to increased levels of circulating lipids, IR, 
inflammation and oxidative stress [6,7]. In agreement with a putative role of oxidative stress in the 
etiology of NAFLD, important antioxidant enzymes and vitamins are decreased in obese and NAFLD 
patients [4,8,9]. 
Vitamin C (VitC) is a water-soluble, chain-breaking antioxidant capable of scavenging essentially  
all physiologically relevant free radicals [10]. Additionally, it serves as donor of reducing equivalents in 
multiple enzymatic reactions, of which its role in proline and lysine hydroxylation during collagen 
synthesis is probably most widely known [11]. Humans and a few other species are unable to synthesize 
VitC, and must instead acquire it through dietary means. Inadequate dietary intake results in VitC 
deficiency defined as plasma levels below 23 μM [12]. Cross-sectional population studies have shown 
that about 10%–20% of the western population can be diagnosed with VitC deficiency and that poor 
VitC status is associated with increased all-cause mortality [13–17] Moreover, the prevalence of VitC 
deficiency in specific subgroups may be considerably higher, potentially enhancing susceptibility to 
oxidative stress and disease [18]. Accordingly, VitC status correlates inversely with e.g., BMI and is 
significantly decreased in obese compared with lean individuals [9,19–22]. Thus, the apparent link 
between obesity, NAFLD and oxidative stress suggests that NAFLD progression may be accelerated by 
poor VitC status. 
The aim of this review is to discuss the current data from human and animal studies in relation to a 
putative role of VitC in the development of NAFLD. 
2. Obesity, Systemic Inflammation and NAFLD 
2.1. Obesity and Systemic Inflammation 
Obesity is primarily a consequence of a sedentary lifestyle and the intake of an excess amount of 
calories. As a result, unused resources are accumulated as fat in adipose tissue, facilitating adipocyte 
hypertrophy and hyperplasia, alongside increased production of chemokines, cytokines, reactive oxygen 
species (ROS), hypoxia and cell death, ultimately leading to macrophage infiltration and adipocyte 
dysfunction [23–25]. Macrophages initiate and maintain inflammation by secreting a variety of cytokines, 
such as tumor necrosis factor α (TNFα) and interleukin (IL) 6 [2,23] At the same time, dysfunctional 
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adipocytes increase their secretion of pro-inflammatory cytokines, while decreasing secretion of  
anti-inflammatory cytokines [24,26]. Decreased secretion of adiponectin by adipocytes and concurrent 
interference with the insulin signaling pathway by inflammatory cytokines promotes the development 
of IR [2,27,28]. Furthermore, inflammation of the adipose tissue may participate in the induction of 
hepatic IR as well [29]. Inflammation, IR and adipocyte hypertrophy per se can increase the rate of 
lipolysis and subsequent release of free fatty acids (FFA) [2,30,31]. FFAs have been shown to directly 
activate macrophages through Toll-like receptors 2 and 4 and enhance the production of inflammatory 
cytokines [32]. Thus, a vicious cycle is established: Adipocyte dysfunction induces a low-grade 
inflammation, which increases the release of FFA. In turn, the FFAs stimulate macrophage activation 
and additional production of inflammatory cytokines [5] (Figure 1). Ultimately, this may result in a state 
of chronic, low-grade systemic inflammation and oxidative stress [33]. Low levels of antioxidants may 
enhance oxidative stress, aggravating an already vulnerable state of redox imbalance. 
Figure 1. Propagation of low-grade systemic inflammation from adipose tissues. 
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Dietary induced dyslipidemia leads to increased fat deposition and promotes hypertrophy and 
hyperplasia of adipocytes as well as cellular reprogramming leading to altered secretory functions of 
adipocytes. The tissue expansion and associated adipocyte dysfunction increases the release of inflammatory 
cytokines (such as IL6 and TNFα) and activates macrophages. Furthermore, release of the anti-inflammatory 
adipokines, e.g. adiponectin, is decreased. This induces a state of low-grade systemic inflammation, 
which in turn compromises insulin sensitivity and increases lipolysis in adipose tissues, increasing the 
release of free fatty acids (FFA) and exacerbating the dietary induced dyslipidemia. Moreover, FFAs 
also promote macrophage activation by binding to Toll-like receptors 2 and −4, further propagating the 
production of inflammatory cytokines. Thus a viscous cycle is established in which dyslipidemia and 
systemic inflammation is propagated through dysfunctions in adipocyte metabolism. 
Multiple cross-sectional studies have found decreased levels of VitC and several other antioxidants 
in obese men and women, and observed an inverse correlation between VitC levels and BMI, waist 
circumference and body fat percentage [15,19–22]. The third Glasgow MONICA population survey 
investigated the plasma VitC status of men and women aged 25–74 years and found 44% of the 
participants (n = 1267) to be VitC deficient, with a VitC plasma concentration below 23 μM [15]. 
Additionally, using data from 8808 U.S. adult men and women participating in the Third National Health 
and Nutrition Examination Survey (NHANES III), Ford et al. reported that the metabolic syndrome was 
associated with decreased levels of VitC and other antioxidants such as vitamin E (VitE) [34]. Dietary 
habits may be an important factor contributing to the poor VitC status in obesity. Obese individuals have 
been shown to consume less dietary VitC [22]. Similarly, obese women were found to consume less 
fruits and vegetables compared to lean controls [35]. 
A putative role of VitC in inflammation has also been suggested, since VitC levels have been  
found to be inversely associated with inflammatory markers such as C-reactive protein (CRP) and 
myeloperoxidase [19,22]. Furthermore, VitC may be involved in the regulation of the key adipokine, 
adiponectin, supported by a recent study reporting dietary VitC intake to correlate with adiponectin 
levels in adolescent girls [36]. In vitro studies have suggested that VitC increases the secretion of  
high molecular weight (HMW) adiponectin in fully differentiated human adipocytes without changing  
total adiponectin secretion [37]. Contrary to this, however, supplementation with VitC (500 mg/day)  
in obese patients did not change adiponectin levels [21]. Quantification of total adiponectin, instead of  
the bioactive HMW isomer alone, may account for the conflicting results. Alternatively, the dose of 
VitC might have been too low, as 1000 mg/day was shown to improve several other metabolic 
parameters in patients with type 2 diabetes, i.e., HbA1c, fasting blood sugar, serum insulin, triglycerides 
(TG) and low-density lipoprotein (LDL) [38]. Further cell studies have shown that increased oxidative 
stress decrease the expression of adiponectin mRNA in adipocytes and that adiponectin levels are 
inversely correlated with 4-hydroxynoneal, a maker of lipid peroxidation [39]. Adiponectin levels were also 
inversely associated with the severity of hepatic steatosis and necroinflammation [40]. Thus, a role of 
VitC in adiponectin regulation could have important effects on progression of inflammation, IR  
and NAFLD. 
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2.2. NAFLD 
NAFLD is estimated to affect 6% to 33% (median 20%) of the world’s population and constitutes the 
most common liver disease in the western world [41,42]. NAFLD comprises a cluster of hepatic conditions 
ranging from simple, initially benign and reversible steatosis to hepatocyte ballooning, Mallory bodies, 
fibrosis and inflammation in non-alcoholic steatohepatitis (NASH), [6,43–45]. However, in some 
patients, hepatic steatosis progresses to NASH, increasing the risk of hepatic cirrhosis and hepatocellular 
carcinoma [43,46]. NAFLD is strongly associated with obesity, dyslipidemia, IR, oxidative stress, 
inflammation and the metabolic syndrome [47,48]. Indeed, the prevalence of NAFLD in obese patients 
has been reported to be 74%, the amount of visceral adipose tissue in particular being highly correlated 
with increased risk of NAFLD [6,49]. The pathogenesis of NAFLD is not yet completely understood. 
However, it is currently believed that initial hepatic fat accumulation is followed by multiple parallel 
hits that promote inflammation and disease progression. The most important events believed to be 
involved in this process include; IR, increased FFA, dietary factors, cytokines derived from the adipose 
tissue and ROS formation [7]. 
IR is a key mechanism in hepatic dyslipidemia. Expectedly, diabetic patients have an increased 
prevalence of NAFLD compared to non-diabetic individuals, supporting the link between IR and 
NAFLD [50]. While IR increases circulating levels of FFAs, hyperinsulinemia during IR, paradoxically, 
apparently inhibits hepatic lipid oxidation and increases de novo lipogenesis [51]. Concurrently, 
saturation of very-low-density lipoprotein (VLDL) secretion may facilitate lipid accumulation as  
well [52]. In patients with NAFLD, the majority of hepatic lipids originate from circulating FFA [53]. 
FFA from visceral adipose tissue can drain directly into the portal vein and be transported straight to the 
liver. As hepatocytic FFA uptake is mediated by passive diffusion, increased FFA levels result in 
increased FFA uptake, which is subsequently stored as TG [6,54]. Interestingly, a meta-analysis of 
clinical trials investigating the effect of VitC intervention on LDL, high-density lipoprotein (HDL) and 
TGs in patients with hypercholesterolemia suggested that VitC supplementation can reduce the 
concentration of lipids in circulation (TG and LDL-C) [55]. Additionally, adipose tissue-derived 
cytokines may contribute to the development of NAFLD, and inflammation of the adipose tissue may 
indeed precede hepatic inflammation [56–58]. Adiponectin has been shown to reduce ectopic hepatic 
lipid accumulation, systemic IR and inflammation [59]. In addition, TNFα and IL6 have received much 
attention as putative key cytokines involved in hepatic lipid accumulation, inflammation and IR [60]. 
Dietary factors also play an important role in NAFLD. High dietary fructose, trans-fatty acids, and 
cholesterol have all been found to contribute to the development of dyslipidemia, hepatic fat accumulation 
and subsequent disease progression [7,61–65]. FFA and cholesterol not only induce hepatic lipid 
deposition, but may also have injurious effects in the liver, in part by inducing hepatocyte apoptosis, 
lipotoxicity, mitochondrial dysfunction and endoplasmic reticulum stress with subsequent ROS formation 
and inflammation [24,66–71]. Furthermore, activation of hepatic stellate cells and Kupffer cells, e.g., by 
hepatocyte apoptosis and ROS, also appear to promote disease progression through the secretion of 
TNFα, IL6, transforming growth factor β and collagen, which induces inflammation and fibrosis [72] 
(Figure 2). Indeed, increased generation of ROS and lipid peroxidation are believed to be key pathogenic 
components in NAFLD, perpetuating inflammation, fibrogenesis, and development of cirrhosis and 
hepatocellular carcinoma [73,74]. Oxidative stress alone has been found to be associated with NAFLD 
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both in patients with, but also without type 2 diabetes [75]. VitC has been shown to decrease mitochondrial 
ROS formation and stimulate the activity of manganese superoxide dismutase (SOD) and glutathione 
peroxidase (GPx) in isolated rat liver mitochondria [76]. However, dietary intake of VitC and VitE has 
been reported to be lower in NAFLD patients, potentially predisposing them to oxidative stress [77,78]. 
Figure 2. Putative effects of vitamin C deficiency on the progression of NAFLD. 
 
As co-factor for the 7α-hydroxylase, catalyzing the conversion of cholesterol to 7α-hydroxycholesterol, 
VitC deficiency may increase circulating levels of cholesterol (CHOL) by reducing its excretion through 
the bile. Systemic inflammation and dyslipidemia is propagated through adipocyte dysfunction, e.g., 
releasing fatty acids (FFA) and inflammatory cytokines to the blood stream. Moreover, by affecting 
adiponectin regulation, lack of VitC may further increase dyslipidemia, systemic inflammation and 
oxidative stress. As VitC is also a powerful antioxidant, deficiency per se promotes cellular oxidative 
stress, e.g., in the liver. The excess lipids induce mitochondrial dysfunction and stress of the endoplasmic 
reticulum (ER) further propagating hepatic oxidative stress and inflammation. FFA and CHOL is taken 
up by hepatocytes and processed to be exported from the liver by VLDL. When overloaded, hepatic 
VLDL export is saturated and lipids are accumulated in hepatocytes. Ultimately, NAFLD progression is 
driven by increased oxidative stress and inflammation, promoting activation of hepatic stellate and 
Kupffer cells, which alongside an increased hepatic production of TNFα, IL6, transforming growth 
factor β and collagen, amplifies the induction of cellular damage and fibrosis. Combined with key 
pathogenic changes taking place during the advancement from simple steatosis (NAFLD) to 
steatohepatitis (NASH), e.g., hepatocyte ballooning, formation of Mallory bodies and fibrosis, NASH 
may progress even further to hepatic cirrhosis and hepatocellular carcinoma. 
Consistent with this notion, a number of investigators have found that markers of oxidative damage 
such as malondialdehyde (MDA) and protein carbonyls are elevated, while antioxidants like catalase 
and SOD are decreased in the plasma and livers of animals and humans with NAFLD [8,65,79,80].  
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This has led to the hypothesis that VitC therapy could prove beneficial in the treatment of NAFLD 
(Figure 2). 
3. Does Vitamin C Deficiency Promote NAFLD? 
3.1. Animal Studies of Vitamin C Deficiency 
Several in vivo studies have investigated the role of poor VitC status in relation to dyslipidemia  
and NAFLD (Table 1). Like humans, guinea pigs are unable to synthesize VitC due to a non-functional 
gene encoding for L-gulonolactone oxidase (gulo), making them an excellent model for the study of VitC 
deficiency. Moreover, with regards to, e.g., cholesterol distribution, activity of enzymes involved in 
lipoprotein metabolism, LDL receptor binding domain characteristics and cholesterol synthesis, guinea 
pigs are comparable to humans in contrast to other rodents [81]. Contrary to the guinea pig, the gulo 
gene is functional in mice and rats and both species are able to synthesize VitC. However, the effect of 
VitC deficiency can be examined in genetically engineered rodent models, although the validity and 
human relevance of such models may be difficult to assess. 
Guinea pigs kept on a diet without VitC for 4 weeks showed elevated levels of hepatic cholesterol 
and TG compared to control animals on a VitC supplemented diet [82]. Similarly, another study in 
guinea pigs showed increased hepatic triacylglycerol and cholesteryl esters after 6 weeks of VitC 
deficiency [83]. Scurvy can be avoided by supplementing the diet with small amounts of VitC, allowing 
investigators to study the long-term effects of non-scorbutic VitC deficiency. After up to 31 weeks on 
such a diet, guinea pigs had elevated levels of TG in the liver, thoracic aorta and serum. This was due to 
decreased conversion of cholesterol to bile acid, revealing a crucial role of VitC in this process [84]. 
Specifically, VitC is a co-factor for the 7α-hydroxylase catalyzing the conversion of cholesterol to  
7α-hydroxycholesterol, constituting the rate-limiting step in bile acid formation, and thus, VitC deficiency 
results in reduced excretion of cholesterol in animals [85]. The addition of cholesterol to a VitC deficient 
diet exacerbated the effects of VitC deficiency per se by increasing the amount of hepatic TG, cholesterol, 
focal fibrosis and proliferation of connective tissue. Moreover, high dose (100 mg/day, p.o.) of VitC 
significantly diminished these changes [86]. Interestingly, dietary cholesterol also appears to have effects 
on the VitC status. In a long-term dietary intervention study in guinea pigs, high cholesterol fed animals 
consistently showed 33% (range 27%–43%) lower plasma and liver VitC concentrations compared to 
control animals regardless of low or high dietary VitC intake [87]. In the osteogenic disorder shionogi 
(ODS) rat—a mutant rat strain unable to synthesize VitC—VitC deficiency with or without cholesterol 
and cholic acid supplementation for 19 days increased hepatic cholesterol and total lipids [88]. 
Furthermore, regardless of the amount of cholesterol added to the diet, Uchida et al. did not find any 
effect of VitC relating to changes in hepatic lipids in ODS rats [89]. These discrepancies may reflect the 
significant differences between guinea pigs and rats in the way lipids are handled and stored [90,91]. 
Collectively, the above results suggest that VitC is involved in the regulation of both circulating and 
hepatic lipid homeostasis, supporting VitC as an important factor in the development of NAFLD. 
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Table 1. Animal studies of vitamin C deficiency. 
Species Age/Weight Design Outcome Ref. 
Guinea Pigs 200–300 g 
Control (VitC 5 mg VitC/day)  
Deficient (0.5 mg VitC/day)  
High VitC (100 mg VitC/day) ± 100 mg chol/day  
Duration: 16 weeks 
VitC deficiency, liver: TG ↑ Chol ↑ PL ↔  
VitC deficiency + chol, liver: TG ↑ Chol ↑ PL ↔ Histology reveal 
fat infiltration, local necrosis and proliferation of connective tissue 
[86] 
Guinea Pigs 400–450 g 
Control (1000 mg VitC/kg diet)  
VitC deficient (0 mg VitC/kg diet)  
VitC high (25,000 mg VitC/kg)  
Duration: 4 weeks 
VitC deficiency, liver: Chol ↑ TG ↑  
VitC deficiency, serum: Chol ↑ TG ↑ HDL ↓ LDL ↑ VLDL ↓ 
[82] 
Guinea Pigs 300–450 g 
Control (10 mg VitC/day)  
Deficient (0.5 mg VitC/day)  
Duration: 22, 28 or 31 weeks 
VitC deficiency, liver/serum/thoracic aorta: Chol ↑ [84] 
Guinea Pigs ? 
Control (660 mg VitC/kg diet)  
Deficiency (33 mg VitC/kg diet)  
High (13,200 mg VitC/kg diet)  
Duration: 5 weeks 
VitC deficiency, liver: TBARS ↑ MDA ↑ protein carbonyls ↑ [92] 
Guinea Pigs 250–300 g 
Control (25 mg VitC/kg/day)  
Deficiency (0 mg VitC/kg/day)  
Duration: 21 days 
VitC deficiency, liver: TBARS ↑ [93] 
Guinea Pigs 600–700 g 
Control (500 mg VitC/kg diet)  
Deficiency (50 mg VitC/kg diet)  
Duration: 6 weeks 
VitC deficiency, liver: TAG ↑ CE ↑ FC ↔ [83] 
Guinea Pigs 12 weeks 
High or low fat diet with different VitC:  
Low (100 mg VitC/kg diet)  
High (691 mg VitC/kg diet)  
Duration: 6 months 
High fat diet, liver: VitC ↓ [87] 
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Table 1. Cont. 
Mice, SMP30−/− 
and WT 
30 days 
SMP30−/− or WT ±1.5 mg/L VitC in water  
Duration: 57 days 
VitC deficiency, liver: protein carbonyl ↑ SOD-activity ↑ Cu  
Zn-SOD protein expression ↑ TBARS ↔, CAT protein 
expression ↓ 
[94] 
Mice, Gulo−/−  
or WT 
20–21 
weeks 
16 weeks on western diet, then:  
Control (0.33 g VitC/L in drinking water)  
Deficiency (0 g VitC/L in drinking water)  
Duration: 3 weeks 
VitC deficiency: GSH ↔ MDA ↑ F2- an F4-isoprostanes ↔ [95] 
Mice, Gulo−/− Newborn 
Control Gulo+/+ (0 mg VitC)  
Deficiency Gulo−/− (0 mg VitC)  
Duration: 18 days 
Gulo−/−, liver: MDA ↑ protein carbonyl ↑ sulfhydryls ↔ GSH ↑ [96] 
Rats, ODS  
or WT 
6 weeks 
ODS fed 0, 50, 300, 3000 mg VitC/kg diet ± 0.5% 
chol and 0.25% cholic acid  
WT fed 0 mg VitC/kg diet ± 0.5% chol and 0.25% 
cholic acid  
Duration: 19 days 
VitC deficiency, liver: Chol ↑/↔ total lipids ↑/↔  
VitC deficiency, serum: Chol ↔ HDL-C ↔  
VitC deficiency + chol/cholic acid, liver: Chol ↑, total lipids ↔  
VitC deficiency + chol/cholic acid, serum: Chol ↑, HDL-C ↑ 
[88] 
Rats, ODS 6 weeks 
Control 300 mg VitC/kg diet  
Deficient 0 mg VitC/kg diet  
Duration: 14 days 
VitC deficiency, liver: CINC-1 ↑ Apo-A1 mRNA ↓ ApoE 
mRNA ↔ 
[97] 
Rats, ODS  
or WT 
9 weeks 
Control (30 mg VitC/L in drinking  
water ± 0.5% chol  
Deficiency 0 mg/L in drinking water  
Duration: 3 weeks 
VitC deficiency, liver: Chol ↔ TG ↔ PL ↔  
VitC deficiency, serum: Chol ↑ Total lipoprotein ↓  
HDL ↓IDL ↓ LDL ↑ VLDL ↓  
VitC deficiency + chol did not affect serum levels further. Chol 
feeding, regardless of VitC status, increase hepatic lipids 
[89] 
CAT: Catalase. Chol: Cholesterol. CE: cholesteryl ester. CINC-1: Cytokine-induced neutrophil chemoattractant-1. FC: Free cholesterol. GSH: Glutathione. Gulo:  
L-gulonolactone oxidase HDL: High-density lipoprotein. IDL: Intermediate-density lipoprotein. LDL: Low-density lipoprotein. MDA: Malondialdehyde. ODS: Osteogenic 
Disorder Shionogi. PL: Phospholipids. SMP30: Senescence marker protein. SOD: Superoxide dismutase. TAG: Triacylglycerol. TBARS: Thiobarbituric acid reactive 
substances. TG: Triglyceride. VitC: Vitamin C. VLDL: Very-low-density lipoprotein. WT: Wild type; Ref.: Reference; ↓ Decrease; ↑ Increase; ↔ No change.
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In accordance with a central role in the prevention of oxidative stress, VitC deficiency has been  
shown to cause a reduction in both expression and activity of various antioxidant enzymes with a 
concurrent rise in markers of oxidative stress. Thus, 3–5 weeks of VitC deficiency caused increased 
levels of thiobarbituric acid reactive substance (TBARS), MDA and protein carbonyls in the liver of 
guinea pigs [92,93]. Oxidative stress was also evident in the liver of gulo−/− mice without access to VitC 
for 57 days. Protein carbonyls, but not TBARS, were increased in the livers of these animals, alongside 
decreased catalase protein expression compared to WT or gulo−/− supplemented controls [94]. However, 
SOD activity was increased, likely as a compensatory mechanism [94]. Indeed, SOD appears to play an 
important role in NAFLD as increased hepatic fibrosis is found in NASH patients with mutations in the 
gene coding for SOD2 [98]. Pierce et al. found increased hepatic MDA in VitC deficient gulo−/− mice 
placed on a western diet, but with no change in glutathione or isoprostanes [95]. However, other authors 
report an increase of glutathione a long with increased MDA and protein carbonyls in livers of gulo−/− 
mice deprived of VitC for similar periods of time [96]. These differences between studies may be 
attributed to different diet compositions and age of the animals, i.e., a western type diet and 4–5 weeks 
old animals vs. normal chow and newly born animals, respectively. The considerable number of studies 
reporting increased protein carbonyls, MDA and TBARS in VitC deficient animals, support that VitC 
has a protective effect against hepatic protein and lipid oxidation. This may be of significance as lipid 
oxidation has been shown to occur in NAFLD and even correlate with the severity of liver 
necroinflammation and fibrosis [99]. Furthermore, keeping ODS rats on a VitC free diet for 14 days 
resulted in increased cytokine-induced neutrophil chemoattractant-1 (CINC-1), a potent inflammatory 
chemokine, in serum, liver and spleen. Thus, VitC deficiency may mediate the infiltration and accumulation 
of neutrophils with subsequent inflammatory damage in some tissues [97]. 
3.2. Animal Studies of VitC Intervention and NAFLD 
Methionine and choline are essential for hepatic β-oxidation and VLDL production. Expectedly, 
methionine and choline deficient (MCD) diets cause accumulation of intra-hepatic lipids and decreased 
VLDL synthesis [43]. Rezazadeh and coworkers fed rats a MCD diet for 10 weeks, and randomized 
animals to receive VitC or no supplementation for an additional eight weeks on the diet [100].  
While VitC supplementation significantly decreased hepatocellular ballooning and inflammation, liver 
steatosis still persisted. At the same time, hepatic markers of oxidative stress were decreased, while SOD 
and catalase were increased [100]. Similar results were obtained by supplementing rats placed on a MCD 
diet with VitC for 10 weeks. The authors also found that VitC treatment significantly increased 
glutathione reductase (GR) and GPx activity [101]. Moreover, VitC treatment resulted in a significant 
decrease in circulating liver enzymes, TG and LDL, showing a protective effect of VitC supplementation 
on the MCD diet-induced dyslipidemia [100,101]. Conversely, rats fed a choline deficient diet for  
4 weeks with concurrent VitC supplementation did not show any improvements in serum TG or aspartate 
aminotransferase, even though hepatic steatosis was ameliorated and oxidative stress reduced [102]. 
However, the studies differ considerably in diet composition, duration and rat strain used, confounding 
compatibility between findings. 
Imbalance of the antioxidant status, similar to that observed in the animal studies, has also been found 
in patients with steatosis while antioxidant status is even further compromised in NASH [80]. Animal 
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models utilizing MCD or choline deficient diets to induce NAFLD appear to present a similar pathology, 
but the pathogenesis is different from the human situation. Additionally, most animals lose weight on 
the MCD diet, contrary to the human situation, in which many NAFLD patients are obese. Results may 
therefore not be directly translatable. 
Guinea pigs placed on an atherogenic diet, high in fat and cholesterol, for 4 months developed 
dyslipidemia with elevated serum cholesterol and phospholipids in addition to elevated hepatic levels of 
cholesterol, phospholipids and TG [103]. VitC deficiency exacerbated the dyslipidemia and hepatic 
consequences, but high VitC reduced the severity of both dyslipidemia and hepatic lipid accumulation [103]. 
It is noteworthy, that extremely high doses of VitC (13,200 mg/kg diet) have been shown to decrease 
hepatic markers of oxidation to the same degree as normal VitC doses in guinea pigs, but also cause a 
reduction of body weight and GR activity, similarly to what was observed in the VitC deficient  
animals [92]. It is possible that the very high dose of VitC caused adverse effects in the guinea pigs,  
e.g., gastrointestinal disturbances and osmotic diarrhea [104,105], which could affect bodyweight and 
general physiology, however, this was not reported by the authors. Conversely, Roomi et al. did not 
report any adverse effects of a mega-dose of VitC (25,000 mg VitC/kg diet) in guinea pigs [82]. Contrary 
to guinea pigs, supplementation with high levels of VitC in ODS rats did not reduce hepatic cholesterol 
to a greater extent that normal VitC levels did [88]. Thus, VitC treatment seemingly reduces hepatic 
oxidative stress, but have variable effect on hepatic steatosis, likely depending on the employed method 
of induction, i.e., a high fat diet versus a MCD or MD diet (Table 2). 
3.3. Epidemiological Studies of VitC Intake and NAFLD 
A number of cohort studies have been carried out, investigating the dietary habits of patients with 
NAFLD. Results are conflicting; some studies indicate suboptimal VitC intake by NAFLD patients 
while others do not (Table 3). Using a 7-day food record Musso et al. evaluated dietary habits in patients 
with NASH and healthy controls. Among other differences, NASH patients consumed significantly less 
VitC compared to the healthy controls (84.3 ± 43.1 vs. 144.2 ± 63.1 mg) [77]. Males constituted the vast 
majority of the NASH group (24/25 patients) and though below that of healthy controls, dietary intakes 
were close to the recommended daily intake of 90 mg VitC/day, although this was not the case for 
smokers with NASH [77,106]. Contrary to this, Ferolla and colleagues found that intake of VitC in 
NAFLD patients diagnosed with fatty liver, did not meet recommendations when assessed in men and 
women using 24-h dietary recall and food frequency questionnaires (FFQ) [78]. Unfortunately, the lack 
of a control group impedes investigation as to whether low VitC intake was also prevalent in a 
comparable healthy population. Different methodology, ethnicity and patients’ disease stage may 
account for apparent study dissimilarities. Indeed, food records may themselves lead patients to change 
their dietary patterns [107]. 
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Table 2 Animal studies of VitC intervention in NAFLD. 
Species Age/Weight Design Outcome Ref. 
Guinea 
Pigs 
300 g 
Normal or atherogenic diet  
Control (10 mg/kg/day)  
Deficiency (1 mg/kg/day)  
High (25 mg/kg/day)  
VitC administration: Oral  
Duration: 4 months 
Compared to control (normal diet):  
VitC deficiency, liver: TC ↑ TG ↑ PL ↓ serum: TC ↔ TG ↔ PL ↔  
High VitC, liver: TC ↔ TG ↓ PL ↑ serum: TC ↔ TG ↔ PL ↔  
Compared to control (atherogenic diet):  
VitC deficiency, liver: TC ↑ TG ↑ PL ↓ serum: TC ↑ TG ↑ PL ↔  
High VitC, liver: TC ↓TG ↔ PL ↓ serum: TC ↓ TG ↓ PL ↓ 
[103] 
Rats 250–300 g 
Control (MCD diet for 10 weeks, then 8 additional 
weeks of MCD diet + vehicle)  
Treatment (MCD diet for 10 weeks, then 8 additional 
weeks of MCD diet + VitC 30 mg/kg/day)  
VitC administration: Oral  
Duration: 18 weeks 
VitC, liver: ballooning ↓ inflammation ↓ steatosis ↔ SOD ↑ CAT ↑ 
protein carbonyls ↓  
VitC, serum: AST ↓ ALT ↓ ALP ↓ γGT ↓ TC ↓ HDL ↑ LDL ↓ 
[100] 
Rats 250–300 g 
Control (MCD diet + vehicle)  
Treatment (MCD diet + VitC 30 mg/kg/day)  
VitC administration: Oral  
Duration: 10 weeks 
VitC, liver: ballooning ↓ SOD ↑ CAT ↑ GR ↑ GPx ↑ TBARS ↓ 
protein carbonyls ↓  
VitC, serum: AST ↓ ALT ↓ ALP ↓ γGT ↓ TC ↓ HDL ↑ LDL ↓ 
[101] 
Rats 300–350 g 
Control (CD diet + vehicle)  
Treatment (CD diet +30 mg VitC/kg/day)  
VitC administration: Oral  
Duration: 4 weeks 
VitC, liver: prevents steatosis and reduces oxidative stress  
VitC, plasma: AST ↔ TG ↔ 
[102] 
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CAT: Catalase; CD: Choline deficient; GPx: Glutathione peroxidase;  
GR: Glutathione reductase; γGT: Gamma-glutamyl transferase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; MCD: methionine choline deficient;  
PL: Phospholipids; SOD: Superoxide dismutase; TBARS: Thiobarbituric acid reactive substances; TC: Total cholesterol; TG: Triglyceride; VitC: Vitamin C; Ref.: 
Reference; ↓ Decrease; ↑ Increase; ↔ No change. 
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Han and co-workers studied the dietary intake of Korean adults [108] and reported no differences  
in dietary VitC intake between men and women with NAFLD and control subjects However, when 
adjusted for age, job, education level, exercise frequency, smoking status, energy intake and n–3 fatty 
acid intake, VitC intake was negatively associated with the risk of NAFLD in male patients (OR: 4.23;  
p-trend = 0.014) [108]. In children with steatosis or NASH, Vos et al. found dietary intakes of VitC to 
be similar [109]. However, while differences in steatosis grade were not associated with differences in 
VitC intake, significantly increased hepatocyte ballooning was indeed observed in children with decreased 
VitC consumption [109]. In another study, Mager et al. reported that daily recommendations of VitC 
were met by children with NAFLD [110]. However, impaired antioxidant status was implied as measured 
by low levels of red blood cell-glutathione compared to previous reports in healthy children although 
the conclusion is weakened by the lack of paired controls [110]. Da Silva and associates concluded that 
VitC intake was not different between healthy controls and adults with either steatosis or NASH [111]. 
In this study of 74 NASH patients and 27 healthy controls, the intake correlated with median VitC plasma 
concentrations, which did not differ between groups 67.6 and 72.1 μM, respectively [111]. Likewise, 
Madan et al. did not find any differences in VitC plasma levels between 29 NAFLD patients and  
23 healthy controls [112]. Also, the VitC plasma concentrations were found not to correlate with hepatic 
inflammation or fibrosis [112]. However, in another study by Cabakan and co-workers, 105 NASH 
patients had reduced VitC plasma levels alongside increased plasma MDA and nitric oxide compared 
with steatosis patients [113]. It is possible that this reflects an ability of VitC to slow down the 
progression of NAFLD. 
The conflicting results do not allow a definitive conclusion regarding dietary VitC intake. However, 
the NAFLD patients included in the studies mentioned above largely seem to have met recommended 
daily allowance of VitC. Unfortunately, most of the studies only examine the estimated dietary intake 
of VitC and have not actually measured plasma VitC concentrations. It has been suggested that assessments 
of dietary VitC only have a moderate relationship with plasma VitC levels, thus the two measures may 
not describe the VitC status in the same way [114]. Moreover, dietary questionnaires have certain limitations 
and underreporting is known to occur, which may also skew results [107]. As noted previously, oxidative 
stress is increased in NAFLD patients [75]. As such, they may have an increased demand of antioxidants, 
like VitC, and inadequate levels are not likely to be reflected by reports of dietary intake alone.  
Daily doses of VitC between 30 and 100 mg do not result in plasma saturation, leading some 
investigators to propose that the daily recommended dose of VitC be increased from 75 and 90 mg/day 
(US women and men, respectively) [105], to 200 mg/day in healthy individuals [115]. Furthermore, 
small differences in dietary intake of VitC between 30 and 100 mg/day can lead to vastly different 
plasma concentrations, as this interval represents a very steep part of the plasma concentration vs. dose 
curve [115]. Therefore, patients with a daily VitC intake in this area and even corresponding to the 
current recommendation may still be at risk of having plasma VitC concentrations below optimal levels. 
While they may not strictly be VitC deficient, plasma VitC levels between 23 and 50 μM may still leave 
patients vulnerable to disease, as, e.g., the relative risk of heart failure has been shown to increase 
significantly by every 20 μM drop in VitC plasma concentrations [116]. 
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Table 3. Epidemiological studies of VitC status in NAFLD patients. 
Design Groups Outcome Ref. 
Cross-Sectional  
Adults  
Healthy controls (n = 25)  
NASH (n = 25) 
NASH patients consumes less dietary VitC (p = 0.0001) [77] 
Cross-Sectional  
Adults  
NAFLD patients (n = 96) Dietary VitC intake was below recommended levels [78] 
Cross-Sectional  
Adults  
Male healthy controls (n = 63)  
Male NAFLD (n = 103)  
Women healthy controls (n = 116)  
Women NAFLD (n = 66) 
Dietary intake of VitC was not different in men and women with NAFLD compared 
with control (p = 0.666)  
Intake of VitC correlated negatively with the odds-ratio of NAFLD for male patients 
(OR: 4.23, p-trend = 0.014) 
[108] 
Cross-Sectional  
Children  
Steatosis (n = 39)  
Borderline Z3 (n = 27)  
Borderline Z1 (n = 36)  
NASH (n = 47) 
Dietary VitC intake was similar in all groups (p = 0.15) and above recommended levels  
High grade of steatosis was not associated with lower dietary VitC intake (p = 0.97)  
Amount of hepatocyte ballooning increases with lower dietary VitC levels (p = 0.05) 
[109] 
Cross-Sectional 
Children  
NAFLD (n = 38) Dietary VitC intake was in agreement with recommended levels [110] 
Cross-Sectional  
Adults  
Healthy control (n = 27)  
Steatosis (n = 33)  
NASH (n = 41) 
Plasma concentrations of VitC did not differ between groups (p > 0.05)  
Dietary intake of VitC did not differ between groups (p > 0.05) [111] 
Prospective  
Adults  
Healthy controls (n = 23)  
NAFLD (n = 29) 
Plasma VitC concentrations were not different between groups (p = 0.65)  
Plasma VitC concentrations did not correlate with inflammatory grade (p = 0.56) or 
fibrosis stage (p = 0.53) 
[112] 
Cross-Sectional 
Adults  
Fatty liver disease (n = 38)  
NASH (n = 67) 
Plasma VitC concentrations were lower in NASH patients (p = 0.001) [113] 
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; OR: Odds ratio; VitC: Vitamin C; Ref.: Reference. 
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3.4. Clinical Intervention Studies with VitC and NAFLD 
To date, no study has directly examined the effect of VitC treatment alone in NAFLD and compared 
it to a placebo-treated control group. However, studies which combine VitC with other treatment form(s) 
have been conducted (Table 4). A 12 month, double-blinded, randomized controlled trial (RCT) examined 
the differences between placebo and combined treatment with VitC (500 mg/day) and E (600 IU/day) in 
children [117]. Both groups received lifestyle intervention, involving increased physical activity and a 
tailored diet aimed at inducing weight loss or maintaining weight in overweight and normal weight children, 
respectively. Liver brightness (as a measure of lipid accumulation), examined by ultrasound, circulating 
levels of liver enzymes, cholesterol and TG were reduced in both groups compared to baseline, but were 
not significantly different between groups [117]. Subsequently, the study was continued as an open-label 
study for an additional 12 months, but with fewer participants and the inclusion of a post-treatment liver 
biopsy [118]. Compared to baseline, both groups exhibited significant improvements in steatosis grade, 
lobular inflammation, hepatocyte ballooning and liver enzymes, but not in fibrosis scores. However, again 
there were no differences between placebo and treatment group. Thus, VitC and E supplementation are 
seemingly not superior to lifestyle intervention in children with NAFLD [118]. However, due to the 
study design, it is not possible to determine if vitamin treatment is better than no treatment at all. The 
authors rightfully suggested that increased fruit and vegetable consumption, augmented by the new diet, 
may well have minimized the effect of the vitamin treatment [118]. Indeed, VitC absorption is highly 
dose depended and excess amounts are effectively excreted and can therefore not facilitate additional 
health benefits [115]. Harrison et al. examined the effect of VitC (1000 mg/day) in combination with 
VitE (1000 IU/day) versus placebo after 6 months treatment of NASH patients [119]. Lifestyle interventions 
in both groups focused on exercise and a low-calorie diet. Hepatic inflammation, necrosis, fibrosis and 
liver enzymes were not significantly different between the groups. However, a significant, albeit clinically 
modest, intra-group improvement was observed in the vitamin treated group, with regards to hepatic 
fibrosis. On the basis of this result, the authors concluded that VitC and VitE treatment seemingly improves 
hepatic fibrosis in NASH patients [119]. However, this conclusion has been criticized; emphasizing that 
valid conclusion in placebo-controlled trials must be made by comparing treatment and placebo-groups 
rather than with historic data [120]. Interestingly, the fibrosis score was not improved in children with 
NAFLD, when compared to baseline [118]. Both studies implemented lifestyle changes, but doses of 
VitC and E, study duration and participants were different between the two studies. Additionally, the 
children with NAFLD had a low fibrosis score (0–1) at baseline, which may impede detection of potential 
improvements [118]. Importantly, liver physiology, development and the features of NASH may differ 
considerably between children and adults, which could affect study outcomes [121,122]. 
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Table 4. Clinical intervention studies with VitC in NAFLD. 
Design Groups and Intervention Outcome Ref. 
12 months, double-blinded, 
randomized clinical trial 
Children  
Lifestyle intervention + placebo (n = 43)  
Lifestyle intervention + VitC (500 mg/day) and VitE  
(600 IU/day) (n = 45) 
No differences between groups (p > 0.05) [117] 
24 months  
12 month double-blinded 
followed by 12 month  
open-label, randomized 
clinical trial 
Children  
Lifestyle intervention + placebo (n = 28)  
Lifestyle intervention + VitC (500 mg/day) and VitE  
(600 IU/day) (n = 25) 
No differences between placebo and VitE/VitC groups 
(p > 0.05)  
Compared to baseline, treatment improved steatosis 
grade (p < 0.001), lobular inflammation (p < 0.001), 
hepatocyte ballooning (p < 0.001) and NAFLD activity 
score (p > 0.001), but not portal inflammation (p = 0.1) 
and fibrosis stage (p = 0.6). 
[118] 
6 month, double-blinded, 
randomized clinical trial 
Adults  
Lifestyle intervention + placebo (n = 22)  
Lifestyle intervention + VitC (1000 mg/day) and VitE  
(1000 IU/day) (n = 23) 
No differences between placebo and VitC/VitE groups  
(p > 0.05)  
Compared to baseline, VitC/VitE treatment improves 
fibrosis (p = 0.002) 
[119] 
12 months, pilot study  
No control group 
Adults  
VitC (300 mg/day) and VitE (300 mg/day (n = 23) 
Treatment decreased serum ALT (p < 0.0001) and  
hs-CRP (p < 0.005) and improved steatosis (6/10), 
necroinflammation (8/10), fibrosis (4/10). 
[123] 
6 month, open-label, 
randomized study 
Adults  
Ursodeoxycholic acid (10 mg/kg/day) (n = 29)  
VitC (500 mg/day) and VitE (600 IU/day) (n = 27) 
No differences between ursodeoxycholic acid and 
VitC/VitE treatment (p > 0.05) [124] 
4 years, randomized  
clinical trial 
Adults  
NAFLD  
Placebo (n = 36)  
Treatment (1000 mg VitC/day, 
1000 IU VitE/day, 20 mg 
atorvastatin/day) (n = 44) 
Adults  
Normal liver  
Placebo (n = 190)  
Treatment (1000 mg 
VitC/day, 1000 IU 
VitE/day, 20 mg 
atorvastatin/day (n = 185) 
Treatment reduced risk of having moderate to severe 
hepatic steatosis (OR = 0.36, p < 0.017) [125] 
ALT: Alanine aminotransferase; Hs-CRP: High sensitivity C-reactive protein; NAFLD: Non-alcoholic fatty liver disease; OR: Odds ratio; VitC: Vitamin C; VitE: Vitamin 
E; Ref.: Reference. 
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In a pilot study, NASH patients were treated with VitC (300 mg/day) and VitE (300 mg/day) for  
12 months and changes were compared to baseline. BMI remained unchanged, but serum alanine 
aminotransferase and high-sensitivity-CRP were significantly reduced by the antioxidant treatment [123]. 
High-sensitivity-CRP has been shown to be associated with the severity of liver pathology in NASH [126]. 
Ten of the 23 study participants underwent liver biopsy post-treatment and of these, steatosis improved 
in 6/10, necroinflammation in 8/10 and fibrosis in 4/10 [123]. However, the lack of a placebo group 
confounds these findings with time-induced changes and complicates the interpretation of the potential 
effect of the combined VitC and E treatment. The effect of ursodeoxycholic acid (UDCA) (10 
mg/kg/day) compared to that of VitC (500 mg/day) and VitE (600 IU/day) was examined in a 6 month, 
open-label, randomized study [124]. Compared to baseline, both treatments decreased circulating levels 
of liver enzymes without inducing changes in liver echogenicity. Side effects were reported in the UDCA 
treated group, whereas no side effects were reported in the vitamin treated group [124]. This is in 
agreement with other studies reporting that VitC and E are well tolerated [119,123]. Foster and coworkers 
evaluated the combination of atorvastatin (20 mg/day), VitC (1000 mg/day) and VitE (1000 IU/day) [125]. 
CT-scans were used to identify NAFLD. Subsequently, the participants were divided into NAFLD patients 
and normal liver patients. These two groups were further allocated to either the treatment combination 
or placebo. The four groups were reexamined after 2 and 4 years. In patients without NALFD at baseline, 
the treatment had no preventive effect. However, in patients with NAFLD, active treatment significantly 
reduced the prevalence of fatty liver [125]. This is contrary to the result of Ersöz et al., who found no 
improvement in hepatic echogenicity after 6 months of treatment [124]. However, considerably lower 
vitamin doses, duration and different radiological methods were used by Ersöz et al., which may explain 
the conflicting results. However, improvements in hepatic steatosis may of cause, in part be contributed 
to atorvastatin, as hepatic steatosis is associated with dyslipidemia [127]. Indeed, active treatment with 
VitC, VitE and atorvastatin did reduce plasma levels of LDL and cholesterol, while HDL and TG levels 
remained unchanged [125]. Furthermore, treatment with atorvastatin (20 mg/day) alone, improved 
ultrasound echo-patterns in NAFLD patients [128]. Unfortunately, radiological techniques are not able 
to detect small amounts of hepatic steatosis and can therefore not distinguish between the different forms 
of NAFLD [129]. Consequently, the effect of the treatment on more advanced stages of NAFLD  
is unknown. 
4. Conclusion 
Controlled animal experiments support a role of VitC deficiency in the elevation of plasma and 
hepatic lipids, alongside increased hepatic oxidative stress, fibrosis and inflammation. In agreement, 
VitC treatment of liver disease-induced animals has been shown to reduce hepatic markers of oxidative 
stress. Clinical studies of the relationship between VitC deficiency and NAFLD have not been conducted 
and studies of estimated dietary intakes of VitC in NAFLD patients are conflicting. Some studies show 
correlations between VitC intake and NAFLD progression, while others do not. Importantly, only a few 
studies have addressed VitC plasma levels in NAFLD patients [111–113]. The presently available RCTs 
have not found an effect of VitC superior to that of placebo. However, a number of studies do 
demonstrate hepatic improvements compared with baseline, but the use of treatment-cocktails and 
concurrent life-style interventions seriously confound the analysis of VitC specific effects. Additionally, 
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most RCTs have not recorded or reported baseline VitC concentrations and putative effects of VitC 
supplementation cannot be assessed in patients already saturated with VitC due to its non-linear 
absorption kinetics [16]. Therefore, the role of VitC in NAFLD should be investigated in future RCTs 
in which plasma VitC status is controlled for. 
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